Pneumocystis jirovecii

Letter to the Editor
Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead
Gilles Nevez, Solène Le Gal
Letter to the Editor
The Fascinating Echinocandin-Treated Mouse Model of Pneumocystis murina To Understand Pneumocystis jirovecii
Gilles Nevez, Anne Totet, Céline Damiani, Solène Le Gal
Clinical Therapeutics
Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy
Pneumocystis jirovecii pneumonia is a life-threatening opportunistic infection in children receiving immunosuppressive chemotherapy. Without prophylaxis, up to 25% of pediatric oncology patients receiving chemotherapy will develop Pneumocystis jirovecii pneumonia.

Melissa Quinn, J. T. Fannin, Joseph Sciasci, Allison Bragg, Patrick K. Campbell, Delia Carias, Kristine R. Crews, David Gregornik, Sima Jeha, Gabriela Maron, Jennifer L. Pauley, Hope D. Swanson, Joshua Wolf, William Greene
Epidemiology and Surveillance
High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy
Carolina A. Ponce, Magali Chabé, Claudio George, Alejandra Cárdenas, Luisa Durán, Julia Guerrero, Rebeca Bustamante, Olga Matos, Laurence Huang, Robert F. Miller, Sergio L. Vargas

Main menu